NEW YORK (GenomeWeb) – Luminex said on Sunday that it expects to report fourth quarter revenues of around $78 million, up 8 percent from the prior-year quarter, and full-year 2017 revenues of more than $306 million, an increase of 13 percent from the prior year.

The firm said that it expects molecular diagnostics product revenues to rise 12 percent year-over-year to about $44 million. Its MDx sample-to-answer portfolio is expected to grow 33 percent over the prior-year quarter and generate $13 million in Q4.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.